Results 81 to 90 of about 42,544 (264)

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Viral Biomarkers in Chronic HBeAg Negative HBV Infection

Genes, 2018
Viral biomarkers are important tools for monitoring chronic hepatitis B virus (HBV) hepatitis B early antigen (HBeAg) negative infection, both in its natural course as well as during and after treatment. The biomarkers consist of antibodies against viral
E. Hadziyannis, A. Laras
semanticscholar   +1 more source

De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy [PDF]

, 2014
Substantial progress has been achieved in antiviral therapy for chronic hepatitis B; however, options for women of child-bearing age with HBeAg-positive chronic hepatitis B remain a challenge.
Liu, Shuai-Wei, Xie, Yan, Liu, Xiao-Yan, Ding, Xiang-Chun, Xu, Chun-Qiong, Ma, Li-Na   +5 more
core   +1 more source

Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B

Portal Hypertension &Cirrhosis, EarlyView.
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, is achieved by only a minority of patients with chronic hepatitis B (CHB); early identification of likely responders may improve cure rates and reduce costs. However, responses to antiviral therapy vary considerably, necessitating reliable hepatitis B virus (HBV) viral ...
Xinrong Lu, Xin Yang, Qishui Ou, Zhen Xun   +3 more
wiley   +1 more source

Longitudinal changes in virological, biochemical and serological responses in subsequent months of ETV therapy in HBeAg(+) and HBeAg(-) patients at baseline. [PDF]

, 2016
Frequencies of HBV DNA
Paweł Rajewski (3185898), Krzysztof Domagalski (761719), Małgorzata Pawłowska (761720), Beata Smok (3185895), Waldemar Halota (761724), Andrzej Tretyn (761723), Magdalena Wietlicka-Piszcz (819548)   +6 more
core   +1 more source

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux, Nieves Velez de Mendizabal, Aksana Jones, Scott Balsitis, Stephan Schmidt, Justin S. Feigelman, Francine Johansson Azeredo   +6 more
wiley   +1 more source

A Predictive Model to Evaluate the HbeAg Positivity of Chronic Hepatitis B Virus Patients in Clinics: A Cross-Sectional Study

Medicina, 2022
Background and Objective: The study aims to investigate the correlation between Hepatitis B ‘e’ antigen (HBeAg) and HBV DNA levels, and to find a convenient tool to estimate the HBV DNA level for clinicians.
Ning Wang, Jinli Zheng, Yang Huang, Xingyu Pu, Li Jiang, Jiayin Yang   +5 more
doaj   +1 more source

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection

Alimentary Pharmacology &Therapeutics, EarlyView.
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod, Fikadu G. Gudissa, Asiya Jeylan, Nega Berhe, Hailemichael Desalegn, Lasse Rossvoll, Asgeir Johannessen, Niklas K. Björkström, Dag Henrik Reikvam, Annika Niehrs   +9 more
wiley   +1 more source

Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma

Alimentary Pharmacology &Therapeutics, EarlyView.
In 902 patients with HBV‐related HCC undergoing curative resection, antiviral regimens (ETV, TDF, TAF) showed comparable recurrence‐free survival. However, TDF was independently associated with improved overall survival compared with ETV. ABSTRACT Background & Aims The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and ...
Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hye Won Lee   +10 more
wiley   +1 more source

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

Hepatology Research, EarlyView.
We carried out proteomic analysis of serum extracellular vesicles to identify biomarkers predictive of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B receiving nucleos(t)ide analog therapy. Candidate proteins identified through proteomic analysis were subsequently quantified in serum by ELISA.
Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, Satoshi Shigeno, Yuta Myojin, Kazuki Maesaka, Kumiko Shirai, Yuki Makino, Yuki Tahata, Yoshinobu Saito, Takahiro Kodama, Ryotaro Sakamori, Jun Adachi, Tomomi Yamada, Tetsuo Takehara   +21 more
wiley   +1 more source